Does MDwise Cover Forteo (Teriparatide)?

What Is Forteo and Why Is It Prescribed?

Forteo (teriparatide) is a recombinant form of human parathyroid hormone (PTH 1-34). Unlike bisphosphonates, which slow bone resorption, teriparatide works anabolically by stimulating new bone formation. The FDA approved teriparatide for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and women and men with glucocorticoid-induced osteoporosis. FDA approval and labeling information confirms the maximum treatment duration is 24 months over a patient's lifetime.

The Clinical Evidence Behind Teriparatide

The key Fracture Prevention Trial (N=1,637 postmenopausal women) showed teriparatide 20 mcg/day reduced new vertebral fractures by 65% (relative risk 0.35, P<0.001) and nonvertebral fragility fractures by 53% compared with placebo at a median 21 months of treatment. PubMed PMID 11794148 documents these outcomes. Lumbar spine bone-mineral density increased by 9.7% and femoral neck BMD by 2.8% over the same period.

Who Qualifies Clinically?

The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines (endocrine.org guidelines) reserve anabolic agents like teriparatide for patients classified as "very high fracture risk," defined as a T-score at or below -3.0, a prior hip or vertebral fracture, or multiple fractures. Patients who fracture on antiresorptive therapy are also candidates. This clinical threshold matters because insurers, including MDwise, typically align their prior authorization criteria with published clinical guidelines.

How MDwise Pharmacy Benefits Work

MDwise is one of Indiana's contracted Medicaid managed-care entities under the HoosierCare Connect and Hoosier Healthwise programs. Each plan maintains its own preferred drug list (PDL), also called a formulary, which classifies medications by tier and lists any utilization-management requirements such as prior authorization (PA) or step therapy.

Formulary Tier Structure

Medicaid managed-care formularies in Indiana must comply with the CMS Medicaid Managed Care Final Rule and the Indiana Family and Social Services Administration (FSSA) drug-coverage standards. Specialty injectable medications like Forteo are almost universally placed on the highest formulary tier, meaning they require PA before dispensing. A specialty pharmacy (rather than a retail pharmacy) typically dispenses teriparatide even when coverage is approved.

Step Therapy for Osteoporosis Drugs

Most managed Medicaid plans, including those operating in Indiana, require members to first try at least one first-line oral bisphosphonate before approving an anabolic agent. Alendronate (generic, 70 mg weekly) is the most commonly required step-therapy agent because it carries the strongest evidence base for fracture reduction and costs well under $10 per month at the Medicaid rate. Cochrane review PMID 18843626 confirms alendronate reduces vertebral fracture risk by roughly 47% and hip fracture risk by 53% in high-risk postmenopausal women, which is why payers position it as a required first step.

If a patient cannot tolerate oral bisphosphonates (due to esophageal disease, chronic kidney disease with GFR <35 mL/min, or documented GI intolerance), that contraindication must be clearly documented in the PA request to bypass the step-therapy requirement.

Prior Authorization Criteria MDwise Typically Applies

Because MDwise does not publish its complete PA criteria publicly in a single document, the criteria below are drawn from Indiana Medicaid PDL policy documents, FSSA guidance, and standard managed-care practice for teriparatide. Prescribers should always verify current criteria directly with MDwise before submitting a PA.

Documentation the Prescriber Must Submit

1. Diagnosis confirmation. ICD-10 code M80 (osteoporosis with fracture) or M81 (osteoporosis without fracture), supported by a DXA report showing T-score at or below -2.5 at the lumbar spine or femoral neck, or a documented low-trauma (fragility) fracture in the past 24 months.

2. Step-therapy evidence. Medical records or pharmacy claims showing an adequate trial of at least one oral bisphosphonate, typically defined as 6-12 months at a therapeutic dose, OR documented clinical reason the patient cannot use bisphosphonates.

3. Fracture-risk stratification. A FRAX score (available at www.sheffield.ac.uk/FRAX) showing 10-year major osteoporotic fracture probability above 20%, or 10-year hip fracture probability above 3%, supports the PA narrative. The National Osteoporosis Foundation and AACE both use these thresholds. NOF guidelines reference via NIH confirms these intervention thresholds.

4. Prescriber specialty. Some PA reviewers give additional weight to requests from endocrinologists, rheumatologists, or metabolic bone-disease specialists over those from primary-care providers, though primary-care PAs are not automatically rejected.

Duration of Approval and Renewal

Initial PA approval for teriparatide under Medicaid managed-care plans is commonly granted for 6 months, with renewal PA required to continue through the 24-month lifetime maximum. Renewal PA typically requires a repeat DXA or clinical progress note documenting tolerability and continued medical necessity. The FDA label explicitly states that retreatment with teriparatide is not recommended, so cumulative lifetime exposure is capped at 24 months total. FDA labeling PMID 21298078 context

What Happens If MDwise Denies Coverage?

A coverage denial is not the end of the road. Indiana Medicaid members have formal appeal rights under federal Medicaid law and Indiana administrative code.

The MDwise Internal Appeals Process

After a PA denial, the prescriber or member may file a first-level internal appeal within 60 days of the denial notice. The appeal should include any additional clinical records, specialist notes, imaging reports, or peer-reviewed literature supporting medical necessity. Turnaround time for standard appeals is typically 30 days; expedited appeals (when the standard timeline could seriously jeopardize health) must be resolved within 72 hours under 42 CFR 438.408.

State Fair Hearing

If the internal appeal fails, members can request a state fair hearing through the Indiana FSSA Office of Medicaid Policy and Planning. A neutral hearing officer reviews the case independently. CMS Medicaid managed-care member rights guidance guarantees this right to all Medicaid managed-care enrollees nationwide.

Peer-to-Peer Review

Before filing a formal appeal, the prescriber may request a peer-to-peer call with the MDwise medical director or a designated reviewing physician. This call often resolves denials without a formal appeal, particularly when the clinical rationale for bypassing step therapy is clearly articulated. The 65% vertebral fracture reduction seen in the Fracture Prevention Trial (PMID 11794148) and the AACE designation of teriparatide as first-line therapy for very-high-risk patients are useful talking points in these calls.

Cost-Assistance Options When Coverage Is Denied or Incomplete

When MDwise denies coverage or when a member is in a coverage gap, several cost-reduction pathways exist. The framework below organizes options by insurance status.

Lilly Cares Foundation (Manufacturer PAP)

Eli Lilly operates the Lilly Cares Foundation Patient Assistance Program for patients who are uninsured or cannot afford their out-of-pocket costs. Income eligibility thresholds change periodically. Applications are available through the prescriber's office or at Lilly Cares. Patients who are Medicaid-enrolled but in a coverage gap may still qualify in certain circumstances, though manufacturer co-pay cards cannot be used for federally funded programs including Medicaid under the federal anti-kickback statute. OIG guidance on co-pay assistance addresses this restriction.

Generic Teriparatide (Bonsity, Tlando Context)

Alvogen's Bonsity (teriparatide injection) received FDA approval as a generic-equivalent product. FDA Orange Book lists Bonsity as an AB-rated therapeutic equivalent to Forteo. Some Medicaid formularies now prefer or require Bonsity over branded Forteo because of lower acquisition cost. If your PA was filed for brand Forteo, ask MDwise whether the formulary will cover Bonsity without a separate PA under the generic substitution rules.

Romosozumab or Abaloparatide as Alternatives

If teriparatide is not coverable, two other anabolic or dual-action agents exist. Abaloparatide (Tymlos, 80 mcg/day SC) showed a 43% reduction in new vertebral fractures vs. Placebo in the ACTIVE trial (N=2,463) at 18 months. PMID 28518975 reports these results. Romosozumab (Evenity, 210 mg/month SC) reduced vertebral fracture risk by 73% vs. Placebo in the FRAME trial (N=7,180) at 12 months. PMID 28892457 covers FRAME outcomes. Both require separate PAs, but formulary placement may differ from teriparatide's.

How Prescribers Can Maximize Approval Odds

Getting a teriparatide PA approved on the first submission saves weeks of delay. The steps below reflect standard managed-care best practices, not MDwise-specific insider information.

Optimizing the PA Letter

The PA letter should open with the patient's diagnosis, current T-score, and fracture history. It should then state which bisphosphonate was tried, at what dose, for how long, and why it was discontinued or deemed inadequate. AACE 2020 guidelines (endocrine.org) explicitly categorize patients with T-score at or below -3.0 or prior major fragility fracture as "very high risk" warranting anabolic-first therapy. Quoting that guideline language verbatim in the PA letter aligns your clinical reasoning with the standard the plan's medical director will use to evaluate the request.

Bone turnover markers can also strengthen the case. Serum P1NP (procollagen type 1 N-terminal propeptide) above 35 mcg/L at baseline, or serum CTX below 200 ng/L suggesting inadequate antiresorptive response, gives the reviewer objective biochemical evidence of ongoing bone loss. NIH osteoporosis biomarker reference discusses P1NP and CTX clinical interpretation.

Avoiding Common PA Rejection Reasons

The five most common reasons teriparatide PAs are rejected under Medicaid managed-care plans are:

• Incomplete DXA documentation (no T-score listed, or DXA older than 24 months)
• No documented bisphosphonate trial or inadequate trial duration
• Missing ICD-10 code specificity (M81.0 vs. M80.00 matters)
• No FRAX score or fracture-risk quantification
• PA submitted by office staff without a clinical narrative from the treating physician

A complete submission avoids each of these. According to the Journal of Managed Care and Specialty Pharmacy, PA submission completeness is the single strongest predictor of first-pass approval rates across specialty drug categories. PMID 34855561 reports on specialty-drug PA determinants.

Special Populations and Coverage Considerations

Glucocorticoid-Induced Osteoporosis

The FDA label for teriparatide includes an approved indication for glucocorticoid-induced osteoporosis (GIOP) in men and women at high fracture risk. The American College of Rheumatology 2022 GIOP guideline (PMID 35776634) conditionally recommends teriparatide over oral bisphosphonates for very-high-risk GIOP patients. Medicaid PA criteria for this indication may have a lower step-therapy bar because the pathophysiology (PTH suppression, osteoblast apoptosis) is mechanistically distinct from postmenopausal osteoporosis.

Male Osteoporosis

Men represent roughly 20% of osteoporosis cases yet receive far less diagnostic and treatment attention. NIH Osteoporosis and Related Bone Diseases National Resource Center notes that one in four men over 50 will have an osteoporosis-related fracture. Teriparatide is FDA-approved for men with primary or hypogonadal osteoporosis, and MDwise coverage criteria for men should mirror those for women, though documentation of testosterone levels and any history of hypogonadism may strengthen the PA.

Patients with Chronic Kidney Disease

Teriparatide is generally not recommended for patients with severe renal impairment (estimated GFR <30 mL/min/1.73m2) because PTH metabolism depends on renal clearance. PMID 26946443 reviews teriparatide pharmacokinetics in CKD. Paradoxically, bisphosphonate step therapy is also contraindicated in advanced CKD, which creates a therapeutic gap. Prescribers in this situation may need to request a formulary exception rather than a standard PA, arguing that neither bisphosphonates nor teriparatide are appropriate and requesting romosozumab or denosumab as alternatives.

What the Evidence Says About Delaying Anabolic Treatment

One clinical point worth understanding: delay in initiating anabolic therapy causes measurable harm. The sequential treatment literature shows that starting with an antiresorptive and switching later to an anabolic produces smaller BMD gains than anabolic-first sequencing. The DATA-Switch trial (N=94) demonstrated that women transitioning from denosumab to teriparatide gained significantly less spine BMD than those transitioning in the reverse direction. PMID 25941889 reports these DATA-Switch findings. Prescribers can cite this sequence-dependency evidence when arguing that a step-therapy delay is clinically inappropriate for very-high-risk patients.

The AACE guidelines state directly: "Anabolic agents should be considered for initial therapy in patients with very high fracture risk rather than requiring prior antiresorptive treatment." That quotation, from the 2020 AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis (endocrine.org), gives prescribers guideline-level backing to challenge mandatory step therapy for appropriately selected patients.